Comparison of pharmacodynamic parameters for subjects using aspart and lispro
| Pharmacodynamic parameters | Day 1 | P | Day 4 | P | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Aspart | Lispro | Difference (95% CI) | Aspart | Lispro | Difference (95% CI) | |||||||
| AUCGIR (mg/kg) | 982 ± 83 | 919 ± 175 | 63 (−341 to 467) | 0.76 | 839 ± 124 | 854 ± 116 | 15 (−354 to 325) | 0.93 | ||||
| GIRmax (mg · kg−1 · min−1) | 7.3 ± 0.6 | 6.4 ± 1.1 | 0.96 (−1.57 to 3.49) | 0.46 | 7.7 ± 0.9 | 7.3 ± 1.0 | 0.39 (−2.38 to 3.16) | 0.78 | ||||
| TmaxGIR (min) | 101 ± 9 | 92 ± 11 | 9 (−19 to 37) | 0.53 | 79 ± 9 | 79 ± 7 | 0.14 (−23 to 22) | 0.99 | ||||
| Time to discontinuation of exogenous glucose (min) | 263 ± 10 | 246 ± 15 | 16 (−21 to 54) | 0.40 | 208 ± 20 | 214 ± 17 | 6 (−58 to 45) | 0.81 | ||||
| Ti50 (min) | 58 ± 6 | 46 ± 5 | 12 (−3 to 27) | 0.14 | 38 ± 4 | 39 ± 4 | 1 (−12 to 9) | 0.79 | ||||
| Td50 (min) | 199 ± 13 | 191 ± 12 | 8 (−27 to 42) | 0.66 | 136 ± 10 | 168 ± 13 | 32 (−64 to 0.58) | 0.07 | ||||
Data are means ± SE unless indicated otherwise.